Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3629-3642

  Chow, Anthony ^a   Amemiya, Yutaka ^a   Sugar, Linda ^a   Nam, Robert ^a   Seth, Arun ^a  

^a Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Fusion gene; Prostate cancer; RNA sequencing; TMPRSS2:ERG; Whole transcriptome analysis

Indexed keywords

HYBRID PROTEIN; PROTEIN P53; PROTEINASE; RHO GUANOSINE DIPHOSPHATE DISSOCIATION INHIBITOR BETA; TRANSCRIPTION FACTOR ERG; TRANSCRIPTOME; TRANSMEMBRANE PROTEASE SERINE 2; TUMOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; GENE FUSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; WNT SIGNALING PATHWAY;

BINDING SITES; CELL GROWTH PROCESSES; CELL MOVEMENT; HEK293 CELLS; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RHO-SPECIFIC GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; WNT1 PROTEIN;

EID: 84867027935     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB and Lin K: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155: 762- 771, 2011.
2. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A and Wender R: Screening for prostate cancer: The current evidence and guidelines controversy. Can J Urol 18: 5875- 5883, 2011.
3. Rubin MA: Targeted therapy of cancer: New roles for pathologists - prostate cancer. Mod Pathol 21(Suppl 2): S44-S55, 2008. (Pubitemid 351592771)
4. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, Yan J, Talukder S, Turunen M, Taipale M, Stunnenberg HG, Ukkonen E, Hughes TR, Bulyk ML and Taipale J: Genome-wide analysis of ETS-family DNAbinding in vitro and in vivo. EMBO J 29: 2147-2160, 2010.
5. Sharrocks AD, Brown AL, Ling Y and Yates PR: The ETS-domain transcription factor family. Int J Biochem Cell Biol 29: 1371- 1387, 1997.
6. Hollenhorst PC, Ferris MW, Hull MA, Chae H, Kim S and Graves BJ: Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 25: 2147-2157, 2011.
7. Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, Haskard DO, Dejana E, Mason JC and Randi AM: Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111: 3498-3506, 2008.
8. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M and Kallioniemi O: FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-tomesenchymal transition in human prostate cancer cells. Cancer Res 70: 6735-6745, 2010.
9. Yuan L, Sacharidou A, Stratman AN, Le BA, Zwiers PJ, Spokes K, Bhasin M, Shih SC, Nagy JA, Molema G, Aird WC, Davis GE and Oettgen P: RhoJ is an endothelial cell-restricted Rho GTPase that mediates vascular morphogenesis and is regulated by the transcription factor ERG. Blood 118: 1145-1153, 2011.
10. Clark JP and Cooper CS: ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439, 2009.
11. Hart AH, Corrick CM, Tymms MJ, Hertzog PJ and Kola I: Human ERG is a proto-oncogene with mitogenic and transforming activity. Oncogene 10: 1423-1430, 1995.
12. Hermans KG, van MR, van DH, Jenster G, van Weerden WM and Trapman J: TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66: 10658-10663, 2006. (Pubitemid 44876959)
13. Salagierski M and Schalken JA: Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 187: 795- 801, 2012.
14. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM and Rubin MA: Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12: 590-598, 2010.
15. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J and Chinnaiyan AM: Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3: 94ra72, 2011.
16. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and Scher HI: TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 60: 897-904, 2011.
17. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE and Gerald WL: TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69: 1400-1406, 2009.
18. Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, Bouzyk M, Seth A and Leyland-Jones B: Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 102: 570-576, 2010.
19. Sander EE, ten Klooster JP, van DS, van der Kammen RA and Collard JG: Rac downregulates Rho activity: Reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147: 1009-1022, 1999.
20. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA and Seth A: Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 97: 1690-1695, 2007. (Pubitemid 350249347)
21. Bradford JR, Hey Y, Yates T, Li Y, Pepper SD and Miller CJ: A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling. BMC Genomics 11: 282, 2010.
22. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS and Vasioukhin V: A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105: 2105-2110, 2008. (Pubitemid 351439472)
23. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S and Chinnaiyan AM: TMPRSS2-ERG -mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res 71: 5387-5392, 2011.
24. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL and Clements JA: Kallikrein 4 (hK4) and prostatespecific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 12: 631-643, 2005. (Pubitemid 41482997)
25. Kharaishvili G, Simkova D, Makharoblidze E, Trtkova K, Kolar Z and Bouchal J: Wnt signaling in prostate development and carcinogenesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155: 11-18, 2011.
26. Ricks-Santi L, Mason T, Apprey V, Ahaghotu C, McLauchlin A, Josey D, Bonney G and Dunston GM: p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate 70: 1739-1745, 2010.
27. Gasi D, van der Korput HA, Douben HC, de KA, de Ridder CM, van Weerden WM and Trapman J: Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation. PLoS One 6: e16332, 2011.
28. Robinson L, Panayiotakis A, Papas TS, Kola I and Seth A: ETS target genes: Identification of EGR1 as a target by RNA differential display and whole genome PCR techniques. Proc Natl Acad Sci USA 94: 7170-7175, 1997. (Pubitemid 27345287)
29. Ma J, Ren Z, Ma Y, Xu L, Zhao Y, Zheng C, Fang Y, Xue T, Sun B and Xiao W: Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy. J Biol Chem 284: 34600-34606, 2009.
30. Salah Z, Maoz M, Pizov G and Bar-Shavit R: Transcriptional regulation of human protease-activated receptor 1: A role for the early growth response-1 protein in prostate cancer. Cancer Res 67: 9835-9843, 2007. (Pubitemid 47621231)
31. Zheng C, Ren Z, Wang H, Zhang W, Kalvakolanu DV, Tian Z and Xiao W: E2F1 induces tumor cell survival via nuclear factor-kappaB- dependent induction of EGR1 transcription in prostate cancer cells. Cancer Res 69: 2324-2331, 2009.
32. Vetter M, Blumenthal SG, Lindemann RK, Manns J, Wesselborg S, Thomssen C and Dittmer J: Ets1 is an effector of protein kinase Cá in cancer cells. Oncogene 24: 650-661, 2005. (Pubitemid 40188569)
33. Cho HJ, Baek KE and Yoo J: RhoGDI2 as a therapeutic target in cancer. Expert Opin Ther Targets 14: 67-75, 2010.
34. Xu SG, Yan PJ and Shao ZM: Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using twodimensional differential gel electrophoresis. J Cancer Res Clin Oncol 136: 1545-1556, 2010.
35. Said N, Sanchez-Carbayo M, Smith SC and Theodorescu D: RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest 122: 1503-1518, 2012.
36. Lin R, Maeda S, Liu C, Karin M and Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26: 851-858, 2007.
37. Xu Q and Reed JC: Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. Mol Cell 1: 337-346, 1998. (Pubitemid 128378882)
38. Grzmil M, Thelen P, Hemmerlein B, Schweyer S, Voigt S, Mury D and Burfeind P: BAX inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am J Pathol 163: 543-552, 2003. (Pubitemid 36909416)
39. Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF and Gleason DF: Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer. Prostate 48: 274-284, 2001. (Pubitemid 32816553)
40. Ouyang X, Jessen WJ, Al-Ahmadie H, Serio AM, Lin Y, Shih WJ, Reuter VE, Scardino PT, Shen MM, Aronow BJ, Vickers AJ, Gerald WL and Abate-Shen C: Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res 68: 2132-2144, 2008. (Pubitemid 351521785)
41. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D and Chinnaiyan AM: á- Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662-1670, 2002. (Pubitemid 34289218)
42. Jiang Z, Li C, Fischer A, Dresser K and Woda BA: Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 123: 231-236, 2005. (Pubitemid 40194084)
43. Kumaresan K, Kakkar N, Verma A, Mandal AK, Singh SK and Joshi K: Diagnostic utility of á-methylacyl CoA racemase (P504S) and HMWCK in morphologically difficult prostate cancer. Diagn Pathol 5: 83, 2010.
44. Makarov DV, Loeb S, Getzenberg RH and Partin AW: Biomarkers for prostate cancer. Annu Rev Med 60: 139-151, 2009.
45. Han J, Jogie-Brahim S, Harada A and Oh Y: Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-êB signaling. Cancer Lett 307: 200-210, 2011.
46. Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810, 2004. (Pubitemid 39488658)
47. Kanehisa M and Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28: 27-30, 2000.
48. Kanehisa M, Goto S, Sato Y, Furumichi M and Tanabe M: KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40: D109-D114, 2012.
49. Yoeli-Lerner M, Chin YR, Hansen CK and Toker A: AKT/protein kinase B and glycogen synthase kinase-3â signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 7: 425-432, 2009.
50. Knudsen KE and Kelly WK: Outsmarting androgen receptor: Creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab 6: 483- 493, 2011.
51. Truica CI, Byers S and Gelmann EP: â-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709-4713, 2000.
52. Jung H, Kim HJ, Lee SK, Kim R, Kopachik W, Han JK and Jho EH: Negative feedback regulation of Wnt signaling by Gâã- mediated reduction of Dishevelled. Exp Mol Med 41 : 695-706, 2009.
53. Salsano E, Paterra R, Figus M, Menghi F, Maderna E, Pollo B, Solero CL, Massimi L and Finocchiaro G: Expression profile of frizzled receptors in human medulloblastomas. J Neurooncol 106: 271-280, 2012.
54. Meek DW: Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer 9: 714-723, 2009.
55. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM and Lau KM: Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of ERK1/2, c-JUN/c- FOS-dependent up-regulation of p21, and induction of G 2 cellcycle arrest. Cell Death Differ 17: 1511-1523, 2010.
56. Yoshiko S and Hoyoku N: Fucoxanthin, a natural carotenoid, induces G1 arrest and GADD45 gene expression in human cancer cells. In Vivo 21: 305-309, 2007. (Pubitemid 46534285)
57. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM and Eble JN: Loss of 14-3-3ó in prostate cancer and its precursors. Clin Cancer Res 10: 3064-3068, 2004. (Pubitemid 38619684)
58. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, Yeh IT, Troyer DA, Olumi AF and Kumar AP: Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 15: 1601-1611, 2009.
59. Kawabata R, Oie S, Takahashi M, Kanayama H, Oka T and Itoh K: Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. Int J Oncol 38: 1489-1500, 2011.
60. Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, Fan L, Idowu M, Ware JL, Kim HS, Lee DY and Oh Y: Identification of a novel cell death receptor mediating IGFBP-3- induced antitumor effects in breast and prostate cancer. J Biol Chem 285: 30233-30246, 2010.
61. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 7: 248- 249, 2010.
62. Dumont P, Leu JI, Della Pietra AC, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003. (Pubitemid 36278852)
63. Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 : 1092- 1100, 1999.